Compositions and methods for activating stimulator of interferon gene-dependent signalling
US-2015056224-A1 · Feb 26, 2015 · US
Methods and compositions for inducing an immune response
US11052149B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11052149-B2 |
| Application number | US-201716334153-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 19, 2017 |
| Priority date | Sep 19, 2016 |
| Publication date | Jul 6, 2021 |
| Grant date | Jul 6, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a composition comprising a) a polyacetal polymer, a polyester polymer and/or a biodegradable polymer; b) a cyclic dinucleotide; and c) an antigen and/or an antibody, as well as methods of using same.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of ameliorating, alleviating, decreasing symptom(s), or delaying progression of an infectious disease, cancer, or an autoimmune disorder that requires activation of the stimulator of interferon genes (STING) pathway, comprising administering to a subject in need thereof an effective amount of a composition comprising: a) acetalated dextran; b) an agonist of the stimulator of interferon genes (STING) receptor and/or a different immunostimulatory agent; and c) optionally, an antigen, wherein the composition is formulated in electrosprayed microparticles. 2. The method according to claim 1 , further comprising administering an antibody to the subject.
Assignees
Inventors
Classifications
Antigen presenting cells [APCs], e.g. dendritic cells or macrophages · CPC title
Cancer antigens · CPC title
Orthomyxoviridae, e.g. influenza virus · CPC title
condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48) · CPC title
Antineoplastic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11052149B2 cover?
- The present invention provides a composition comprising a) a polyacetal polymer, a polyester polymer and/or a biodegradable polymer; b) a cyclic dinucleotide; and c) an antigen and/or an antibody, as well as methods of using same.
- Who is the assignee on this patent?
- Univ North Carolina Chapel Hill
- What technology area does this patent fall under?
- Primary CPC classification A61K31/7084. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).